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Cell culture studies have established NF-κB’s critical role in cancer cell survival and proliferation and 
led to the clinical use of NF-κB inhibitors. However, a paper in this issue of Cancer Cell reveals an anti-
cancer function for NF-κB in a mouse model where NF-κB activity is lost specifically in hepatocytes. 
These studies suggest careful examination of NF-κB inhibitors as a therapeutic modality for cancer.Epidemiological studies have long 
established a link between chronic 
inflammation and cancer. Chronic 
infections with hepatitis B and hepa-
titis C viruses and with Helicobacter 
pylori are major risk factors for hepa-
tocellular carcinomas. Similarly, 
chronic inflammatory diseases like 
ulcerative colitis increase the risk of 
colorectal cancer by approximately 
1% per year. By some accounts, 
15%–20% of cancer deaths are due 
to chronic inflammation. How inflam-
matory mediators activate prolifera-
tive programs remains unclear, but 
recent studies point to important, yet 
seemingly contradictory roles of the 
NF-κB signaling pathway.
The transcription factor NF-κB, 
whose activity was first identified dur-
ing B cell activation, is well known as 
a major regulator of inflammatory as 
well as antiapoptotic gene expression 
(Hoffmann and Baltimore, 2006; Li 
and Verma, 2002). Indeed, abnormally 
high nuclear NF-κB activity is a clini-
cal hallmark of chronic inflammation 
and has been found in many differ-
ent types of cancer cells. Drugs that 
dampen the effect of NF-κB activity 
have been found to be useful additions 
to the chemotherapy regimens of a 
variety of cancers. Steroids, the main-
stay of the anti-inflammatory regimen 
in the clinic and often a component of 
cancer therapies, inhibit NF-κB-acti-
vated gene expression. Similarly, pro-
teasome inhibitors like bortezomib, 
recently approved to treat multiple 
myelomas, block NF-κB activation.
This issue of Cancer Cell contains 
a provocative but thorough study 
that explores the role of NF-κB in liver carcinogenesis in a mouse 
model system (Luedde et al., 2007). 
The authors used a conditional 
knockout approach to eliminate NF-
κB activity in hepatocytes. Surpris-
ingly, they found that lack of NF-κB 
resulted in elevated inflammatory 
cytokine expression and spontane-
ous carcinogenesis in every animal 
within a year. Luedde et al. therefore 
Figure 1. NF-κB in Different Cancer Models
(A) Cell culture models often involve cancer cells in which genetic or biochemical lesions (red 
X) lead to an amplification (triangle) of constitutive NF-κB activity in a cell-autonomous manner. 
Elevated NF-κB activity inhibits apoptosis (skull and crossbones) and drives cellular proliferation 
(green circle indicating cell cycle).
(B) Animal models have highlighted the importance of intercellular signaling. Macrophage-spe-
cific genetic inhibition of NF-κB revealed that tissue-resident macrophages (Kupffer Cells) play a 
major role in controlling antiapoptotic and proliferative activity of early cancerous cells by provid-
ing inflammatory signals (Greten et al., 2004; Maeda et al., 2005; Pikarsky et al., 2004). When 
such early cancerous cells are also subject to tonic developmental signals that are mediated by 
the noncanonical NF-κB pathway, the resulting signaling crosstalk may promote cellular prolifera-
tion and/or tumor development (Basak et al., 2007).
(C) The study in this issue of Cancer Cell (Luedde et al., 2007) presents an animal model that also 
involves cell-cell interactions: NF-κB-inhibition in hepatocytes causes apoptosis in many cells, 
which stimulates compensatory proliferation. Kupffer cells respond to apoptotic bodies with in-
flammatory cytokines that act as growth factors. ROS signaling and JNK activity, both elevated 
due to the loss of NF-κB, further stimulate cell proliferation and may drive genetic instability.Cancer Cell 11, February 2007 ©2007 Elsevier Inc. 99
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pressor, which is in direct contra-
diction to the previously accepted 
model that posits NF-κB as a can-
cer-driving transcription factor.
To study molecular mechanisms 
of human carcinogenesis, a large 
number of experimental model sys-
tems have been developed. Appar-
ent discrepancies in the role of NF-
κB in cancer may be understandable 
when considering the specifics of 
the cancer model systems. 
Cell culture constitutes the sim-
plest model system. Transformed 
human or mouse cells lines, or cell 
lines derived from specific human 
cancers, have revealed a role for NF-
κB in blocking spontaneous apop-
tosis in both chemoresistance and 
proliferation (Figure 1A). Indeed, con-
stitutive NF-κB activity in such cells is 
often correlated with the aggressive-
ness of the cancer, and the cells have 
become addicted to NF-κB. In this 
model system, cells are transformed 
and function autonomously without 
tissue interactions. The relevance 
of these findings to later cancer 
stages was demonstrated in mouse 
model systems, in which induction 
of IκB super-repressor expression 
prevented liver cancer progression 
(Pikarsky et al., 2004), or IKK dele-
tion reduced colitis-associated tumor 
incidence due to increasing epithelial 
apoptosis during tumor promotion 
(Greten et al., 2004).
However, mouse cancer models 
have also revealed the importance 
of intercellular signaling and cell-cell 
interactions within an organ. Interest-
ingly, tissue-resident macrophages 
were shown (by a tissue-specific 
knockout of IKK or expression of 
nondegradable IκB mutant) to pro-
vide inflammatory mediators that 
act as growth signals for chemically 
or genetically induced colorectal 
and liver cancer cells (Greten et al., 
2004; Maeda et al., 2005; Pikarsky 
et al., 2004) (Figure 1B). These stud-
ies began to dissect the cellular and 
molecular signaling network that 
forms the basis for the epidemiologi-
cal link between chronic inflamma-
tion and cancer. How inflammatory 
mediators such as TNF or IL-6 acti-100 Cancer Cell 11, February 2007 ©200vate proliferative programs remains 
unclear, but a recent study points to 
the potential importance of crosstalk 
between canonical and noncanonical 
signaling pathways within the NF-
κB signaling system, through which 
inflammatory stimuli may alter the 
processing of “harmless” tonic devel-
opmental signals to have disease-
causing effects (Basak et al., 2007).
But now, in the present study 
(Luedde et al., 2007), a similar tis-
sue-specific knockout leads to the 
opposite conclusions. In this study, 
NF-κB is genetically blocked only in 
hepatocytes, rendering them highly 
susceptible to apoptosis. However, 
liver, more than many other organs, 
has capacity for regeneration. As 
many, but not all, cells die as a result 
of NF-κB inhibition, survivors are 
able to compensate by undergo-
ing hepatic compensatory prolifera-
tion (Figure 1C). As in HBV-infected 
patients, compensatory hepatocyte 
proliferation increases the risk for 
cancer. In a similar study, partial inhi-
bition of NF-κB led to liver cancer fol-
lowing chemically induced liver dam-
age (Maeda et al., 2005). Thus, these 
studies emphasize the role of tissue 
maintenance and homeostasis in 
carcinogenesis. They also show that, 
although hepatocyte proliferation 
and survival involves NF-κB (Lavon et 
al., 2000), these processes can also 
occur in the absence of NF-κB. In this 
model, liver cancer cells have been 
selected to survive in the absence 
of NF-κB-dependent survival gene 
expression, though it is likely that 
they remain more chemosensitive 
than NF-κB-competent controls.
But how is the cancer risk 
increased in the mouse model used 
by Luedde et al.? There appear to be 
three factors that warrant consider-
ation. First, the present study blocks 
NF-κB activation in one cell type 
but leaves liver-resident monocytes 
(Kupffer cells) intact. As Kupffer 
cells sense the apoptotic hepato-
cytes, they produce inflammatory 
cytokines, such as TNF or IL-6, that 
may act to stimulate proliferation 
of remaining hepatocytes. Indeed, 
the present study shows that, when 
apoptosis in hepatocytes is blocked 7 Elsevier Inc.genetically, carcinogenesis is also 
blocked. Second, NF-κB is known 
to antagonize the activity of JNK, the 
other major stress-inducible signal-
ing pathway, which is known both 
as a proapoptotic and as proprolif-
erative regulator. Indeed, JNK activa-
tion in NF-κB or IKK-deleted cells is 
enhanced, contributing to both the 
apoptotic sensitivity of hepatocytes 
as well as proliferative response of 
survivors. (Similarly, elevated JNK 
activity was shown to mediate hyper-
proliferation of keratinocytes [Zhang 
et al., 2004].) Antioxidant treatment 
inhibits JNK and attenuates liver 
carcinogenesis (Luedde et al., 2007; 
Maeda et al., 2005), and genetic 
deletion of JNK unambiguously 
established the requirement for JNK 
in the ensuing carcinogenesis (Saku-
rai et al., 2006). Finally, we may imag-
ine that NF-κB deficiency may cause 
decreased genomic stability by low-
ering cellular antioxidant capacity, 
thus allowing for cancer mutations 
to arise more quickly. Primary murine 
embryonic fibroblasts deficient in 
NF-κB are more easily immortalized 
by repeated passage and are more 
likely to assume a pretransformed 
state than their wild-type counter-
parts (Gapuzan et al., 2005).
Does the present study provide 
a reason to abandon all anti-NF-κB 
therapeutic strategies, or can the 
results be considered an artifact of 
a cell-type-specific knockout strat-
egy within an organ that contains 
multiple cell types? The importance 
of cell-cell interactions and tissue 
homeostasis, and the ensuing com-
plexity when analyzing cell-type-
specific transgenes, has previously 
been noted in the skin (Schmidt-Ull-
rich et al., 2001; van Hogerlinden et 
al., 1999). However, the degree of 
inhibition upon administering an NF-
κB therapeutic is by no means equal 
in all cells of an organ but dependent 
on cell-type-specific metabolic net-
works and location-specific phar-
macokinetics. The good news is that 
the recent work has drawn attention 
to intercellular signals that represent 
druggable therapeutic opportuni-
ties. The challenge lies in incorpo-
rating the information gleaned from 
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examine the safety and effective-
ness of NF-κB therapeutics. In that 
regard, computational modeling may 
prove useful in integrating the com-
plexity of cell-intrinsic and intercellu-
lar molecular mechanisms, tonic and 
responsive signaling, and pharma-
cokinetics and drug metabolism to 
predict or evaluate the effectiveness 
of therapeutic agents.
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pletely understood but may involve 
the phosphorylation of members of 
the Bcl2 family and activation of the 
mitochondrial apoptotic pathway (Fig-
ure 1). The selectivity of the p38 MAPK 
signaling pathway in tumor suppres-
sion is unclear. However, a new study 
by Dolado et al. (2007) reported in this 
issue of Cancer Cell now demonstrates 
that p38 MAPK selectively functions as 
a sensor of oxidative stress during the 
initiation of tumorigenesis.
Dolado et al. examined the proper-
ties of fibroblasts isolated from p38α−/− 
mice when transformed by an acti-
vated HRasV12 oncogene. They report 
that p38α deficiency caused increased 
proliferation, an increased number of 
foci, an increased ability to form colo-
nies in soft agar, and decreased apop-
tosis. The p38α-deficient cells also 
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sis, but the mechanism is incom-
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